Skip to content

Opening book details…

Can I read MR-proADM as prognostic factor of outcome in COVID-19 patients on EtoBox?

MR-proADM as prognostic factor of outcome in COVID-19 patients by Sozio, Emanuela (author);Tascini, Carlo (author);Fabris, Martina (author);D’Aurizio, Federica (author);De Carlo, Chiara (author);Graziano, Elena (author);Bassi, Flavio (author);Sbrana, Francesco (author);Ripoli, Andrea (author);Pagotto, Alberto (author);Giacinta, Alessandro (author);Gerussi, Valentina (author);Visentini, Daniela (author);De Stefanis, Paola (author);Merelli, Maria (author);Saeed, Kordo (author);Curcio, Francesco (author) is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is MR-proADM as prognostic factor of outcome in COVID-19 patients about?

## Abstract Mid Regional pro-ADM (MR-proADM) is a promising novel biomarker in the evaluation of deteriorating patients and an emergent prognosis factor in patients with sepsis, septic shock and organ failure. It can be induced by bacteria, fungi or viruses. We hypothesized that the assessment of MR-proADM, with or without other inflammatory cytokines, as part of a clinical assessment of COVID-19 patients at hospital admission, may assist in identifying those likely to develop severe disease. A pragmatic retrospective analysis was performed on a complete data set from 111 patients admitted to Udine University Hospital, in northern Italy, from 25th March to 15th May 2020, affected by SARS-CoV-2 pneumonia. Clinical scoring systems (SOFA score, WHO disease severity class, SIMEU clinical phenotype), cytokines (IL-6, IL-1b, IL-8, TNF-α), and MR-proADM were measured. Demographic, clinical and outcome data were collected for analysis. At multivariate analysis, high MR-proADM levels were significantly associated with negative outcome (death or orotracheal intubation, IOT), with an odds ratio of 4.284 [1.893–11.413], together with increased neutrophil count (OR = 1.029 [1.011–1.049]) and WH

Who reads MR-proADM as prognostic factor of outcome in COVID-19 patients?

It is typically read by researchers, students, and practitioners in Biochemistry, Genetics and Molecular Biology.

Author
Sozio, Emanuela (author);Tascini, Carlo (author);Fabris, Martina (author);D’Aurizio, Federica (author);De Carlo, Chiara (author);Graziano, Elena (author);Bassi, Flavio (author);Sbrana, Francesco (author);Ripoli, Andrea (author);Pagotto, Alberto (author);Giacinta, Alessandro (author);Gerussi, Valentina (author);Visentini, Daniela (author);De Stefanis, Paola (author);Merelli, Maria (author);Saeed, Kordo (author);Curcio, Francesco (author)
Publisher
Springer Science and Business Media LLC
Published
2021
Language
EN
Field
Biochemistry, Genetics and Molecular Biology (Life Sciences)

More by Sozio, Emanuela (author);Tascini, Carlo (author);Fabris, Martina (author);D’Aurizio, Federica (author);De Carlo, Chiara (author);Graziano, Elena (author);Bassi, Flavio (author);Sbrana, Francesco (author);Ripoli, Andrea (author);Pagotto, Alberto (author);Giacinta, Alessandro (author);Gerussi, Valentina (author);Visentini, Daniela (author);De Stefanis, Paola (author);Merelli, Maria (author);Saeed, Kordo (author);Curcio, Francesco (author)

Browse all works by Sozio, Emanuela (author);Tascini, Carlo (author);Fabris, Martina (author);D’Aurizio, Federica (author);De Carlo, Chiara (author);Graziano, Elena (author);Bassi, Flavio (author);Sbrana, Francesco (author);Ripoli, Andrea (author);Pagotto, Alberto (author);Giacinta, Alessandro (author);Gerussi, Valentina (author);Visentini, Daniela (author);De Stefanis, Paola (author);Merelli, Maria (author);Saeed, Kordo (author);Curcio, Francesco (author)